Literature DB >> 29892961

PSCArs2294008 T polymorphism increases the risk of bladder cancer in Bai, Dai, and Han ethnicity in China and a potential mechanism.

Junfeng Yang1, Wei Li1, Zhuorui Zhang1, Jie Shen1, Ningnan Zhang1, Min Yang1, Maolin Yang1, Yanhong Yu2.   

Abstract

The aim of this study is to make a comparative evaluation on association of PSCArs2294008 C/T polymorphism with the risk of bladder cancer in Bai, Dai, and Han people in China. A potential mechanism of the T allele risk was also investigated. T allele increased the occurring risk of bladder cancer in Han (OR 1.34; 95% CI 1.17-1.69), Dai, (OR 1.33; 95% CI 1.12-1.70), and Bai (OR 1.14; 95% CI 1.08-1.57) people. T genotype was also observed to associate with invasive bladder cancer in all the three populations (Bai, OR 1.15, 95% CI 1.07-1.87; Dai, OR 1.17, 95% CI 1.05-2.23; Han, OR 1.22, 95% CI 1.10-2.09). PSCA m-RNA levels in T genotype bladder cancer tissues were significantly lower than those in C genotype. An enhancement of PSCA m-RNA level by over-expressing C or T genotype in bladder cancer cells both decreased the cell proliferation and migration, but not affected cell cycle. The increased cell apoptasis due to the over-expression of the two variants was observed. Those change of cell proliferation, migration, and apoptasis was more remarkable in over-expressed C genotype cells than those in over-expressed T genotype. T genotype was genetically high risk to the occurrence of bladder cancer. The decreased PSCA m-RNA levels were involved in the progress of bladder cancer. T allele takes more responsibility for PSCA m-RNA down-regulation to promote cell proliferation and migration and hinder cell apoptasis, thus leading to a higher risk.

Entities:  

Keywords:  Bladder cancer; Cell apoptasis; Cell migration; Cell proliferation; Over-expression; PSCA rs2294008 (C/T) polymorphism

Mesh:

Substances:

Year:  2018        PMID: 29892961     DOI: 10.1007/s13258-018-0653-9

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  26 in total

1.  Prostate stem cell antigen variation rs2294008 associated with the risk of bladder cancer.

Authors:  Maomao Li; Xi Yu; Liangliang Cheng; Yi Huang; Guobin Weng
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.

Authors:  Agnieszka Morgenroth; Marc Cartellieri; Marc Schmitz; Serap Günes; Bernd Weigle; Michael Bachmann; Hinrich Abken; Ernst Peter Rieber; Achim Temme
Journal:  Prostate       Date:  2007-07-01       Impact factor: 4.104

3.  MiR-18a regulates the proliferation, migration and invasion of human glioblastoma cell by targeting neogenin.

Authors:  Yichen Song; Ping Wang; Wei Zhao; Yilong Yao; Xiaobai Liu; Jun Ma; Yixue Xue; Yunhui Liu
Journal:  Exp Cell Res       Date:  2014-03-21       Impact factor: 3.905

4.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Authors:  R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.

Authors:  Essam Elsamman; Tomoharu Fukumori; Toshinori Kasai; Hiroyoshi Nakatsuji; Masa-Aki Nishitani; Kazunori Toida; Nermin Ali; Hiro-Omi Kanayama
Journal:  BJU Int       Date:  2006-06       Impact factor: 5.588

6.  A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population.

Authors:  Chizu Tanikawa; Yuji Urabe; Keitaro Matsuo; Michiaki Kubo; Atsushi Takahashi; Hidemi Ito; Kazuo Tajima; Naoyuki Kamatani; Yusuke Nakamura; Koichi Matsuda
Journal:  Nat Genet       Date:  2012-03-04       Impact factor: 38.330

7.  PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma.

Authors:  Li-Yi Zhang; Jian-Lin Wu; Hai-Bo Qiu; Sui-Sui Dong; Ying-Hui Zhu; Victor Ho-Fun Lee; Yan-Ru Qin; Yan Li; Juan Chen; Hai-Bo Liu; Jiong Bi; Stephanie Ma; Xin-Yuan Guan; Li Fu
Journal:  Carcinogenesis       Date:  2016-01-19       Impact factor: 4.944

8.  Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure.

Authors:  Klaus Golka; Matthias Hermes; Silvia Selinski; Meinolf Blaszkewicz; Hermann M Bolt; Gerhard Roth; Holger Dietrich; Hans-Martin Prager; Katja Ickstadt; Jan G Hengstler
Journal:  Pharmacogenet Genomics       Date:  2009-11       Impact factor: 2.089

9.  Impact of DCC (rs714) and PSCA (rs2294008 and rs2976392) Gene Polymorphism in Modulating Cancer Risk in Asian Population.

Authors:  Vishal Chandra; Jong Joo Kim; Usha Gupta; Balraj Mittal; Rajani Rai
Journal:  Genes (Basel)       Date:  2016-02-16       Impact factor: 4.096

Review 10.  Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?

Authors:  Aleksandra M Dudek; Anne J Grotenhuis; Sita H Vermeulen; Lambertus A L M Kiemeney; Gerald W Verhaegh
Journal:  Int J Mol Sci       Date:  2013-06-10       Impact factor: 5.923

View more
  2 in total

1.  The association of AGO1 (rs595961G>A, rs636832A>G) and AGO2 (rs11996715C>A, rs2292779C>G, rs4961280C>A) polymorphisms and risk of recurrent implantation failure.

Authors:  Chang Soo Ryu; Young Ran Kim; Jung Oh Kim; Hui Jeong An; Sung Hwan Cho; Eun Hee Ahn; Ji Hyang Kim; Woo Sik Lee; Nam Keun Kim
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

2.  SNP rs2920280 in PSCA Is Associated with Susceptibility to Gastric Mucosal Atrophy and Is a Promising Biomarker in Japanese Individuals with Helicobacter pylori Infection.

Authors:  Hajime Isomoto; Takuki Sakaguchi; Tatsuo Inamine; Shintaro Takeshita; Daisuke Fukuda; Ken Ohnita; Tsutomu Kanda; Kayoko Matsushima; Tetsuro Honda; Takaaki Sugihara; Tatsuro Hirayama; Kazuhiko Nakao; Kazuhiro Tsukamoto
Journal:  Diagnostics (Basel)       Date:  2022-08-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.